Larry Todd Edwards - 27 Sep 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Chief Commercial Officer
Signature: /s/ Masaru Matsuda, Attorney-in-Fact for Larry Todd Edwards
Issuer symbol: ARQT
Transactions as of: 27 Sep 2023
Transactions value $: $0
Form type: 4
Filing time: 03 Oct 2023, 21:45:12 UTC
Next filing: 17 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Award	$0	+60K		$0.00	60K	27 Sep 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARQT	Stock Option (right to buy)	Award	$0	+240K		$0.00	240K	27 Sep 2023	Common Stock	240K	$5.58	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units ("RSUs") will vest as to 25% of the RSUs on each annual anniversary of October 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.
F2	The option will vest and become exercisable as to 25% of the shares subject to the option on October 1, 2024, and the remaining options will vest at 2.0833% subject to the options on each monthly anniversary thereafter, subject to Reporting Person's continued service through the applicable vesting date.